Hasselt – MyCellHub welcomes Jacques Parlongue as CEO starting from today. Jacques brings his expertise and track record in managing successful international scale-ups, including growing ten-fold the company N-SIDE during his last assignment. MyCellHub is a modular data management and analysis (SaaS) platform that streamlines and automates complex workflows in the bio-manufacturing industry. It can count among its customers companies like eTheRNA immunotherapies, RD-Biotech, TRU Cleanroom Cleaning and EXO Biologics.
1 million euro for SaaS-platform in biopharma : MyCellHub takes LRM on board in second capital round
Hasselt – MyCellHub raises one million euros from the Limburg Investment Company LRM and its existing shareholders, being Gemma Frisius Fund, KU Leuven, Noshaq SA, CoFoundry NV and The Faktory Fund. MyCellHub is a modular data management and analysis (SaaS) platform that streamlines and automates complex workflows in the bio-manufacturing industry. It can count among its customers companies like eTheRNA immunotherapies, TRU Cleanroom Cleaning and EXO Biologics. The funds will be used to integrate new software developments and focus on marketing, sales and internationalisation.
Developing an efficient cell therapy production platform
Cell therapy (CT), using cultured human cells, is a treatment option that holds great promise for curing a vast number of difficult-to-treat diseases, such as diabetes, Alzheimer’s and ALS, and also for skin reconstruction or promoting recovery from an infarct. While cell therapies are currently moving into clinical practice, the production of cells on a commercial scale poses a major economic and industrial challenge. The new Eurostars project Bioscale will focus on the SCINUS expansion system, for cost-efficient cell culture, to achieve standardised CT production, ultimately leading to improved quality consistency in CT development and a reduced cost of CT commercialisation.
MyCellHub, an innovative data management and analytics platform for the production of biopharmaceuticals such as cell and immune therapies raises €1,1 million by Noshaq, The Faktory, Gemma Frisius Fund and The CoFoundry. The investment will help the KU Leuven spin-off to accelerate the launch of the platform. The MyCellHub ‘software as a service’ platform is an app that uses interactive work instructions to assist operators in sterile production environments and which automates data collection and reporting tasks. This provides significant efficiency gains, especially as more than 90% of bio-manufacturers still report their processes on paper.